

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



思路迪医药

3D Medicines

3D Medicines Inc.

思路迪医药股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

**VOLUNTARY ANNOUNCEMENT
UPDATE ON COMPLETION OF ENFORCEMENT OF THE
ARBITRAL AWARD WITH SELLAS LIFE SCIENCES GROUP, INC.**

This announcement is made by 3D Medicines Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcement of the Company dated July 27, 2026, the Company submitted an arbitration in respect of a dispute arising from the licence agreement with SELLAS Life Sciences Group, Inc. (“**SELLAS**”). The sole arbitrator has dismissed all claims put forward by SELLAS. The tribunal further ordered SELLAS to bear the Company’s costs in the arbitration in the sum of HK\$7,983,004.42 (the “**Award**”).

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has received full settlement of the aforementioned amount, and the arbitral award has been fully paid.

This arbitration exclusively addresses the historical dispute between two parties with a final and binding award and will not affect the validity and subsequent performance of the Licence Agreement. As of the date hereof, the global multi-regional clinical trial (MRCT) of 3D189 has accumulated 78 events, versus the target endpoint of 80 events.

This announcement is released to notify the Company's shareholders and potential investors of the latest corporate development of the Group. Shareholders and potential investors of the Company are reminded to exercise prudence when trading the Company's securities.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, August 18, 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. GONG Zhaolong as executive Director, Ms. ZHANG Wenhua, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.